Harnessing lipid metabolism modulation for improved immunotherapy outcomes in lung adenocarcinoma
Background
While anti-programmed cell death protein-1 (PD-1) monotherapy has shown effectiveness in treating lung cancer, its response rate is limited to approximately 20%. Recent research suggests that abnormal lipid metabolism in patients with lung …